Every Form 4 that AUTOLUS THERAPEUTICS PLC (AUTL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AUTL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AUTL filings page.
Autolus Therapeutics plc (AUTL) reported insider activity by U.S. CCO & Country General Manager Cintia Piccina involving both equity awards and a sale of shares. On September 1, 2026, she completed a derivative transaction relating to 20,000 Restricted Share Units (RSUs), with each RSU representing a contingent right to receive one American Depositary Share (ADS); these RSUs vest in four equal annual installments commencing on September 1, 2026. A related entry records the acquisition of 20,000 ADSs on the same date at $2.35 per ADS following the derivative exercise, and she held 60,000 RSUs afterward. On September 2, 2026, she sold 6,713 ADSs in an open-market or private transaction at $2.336 per ADS, and no Rule 10b5-1 trading plan is reported for these transactions.
Autolus Therapeutics plc director William D. Young received equity-based compensation awards. On June 29, 2026, he was granted options to purchase 47,500 American Depositary Shares at an exercise price of $1.61 per share, vesting in twelve equal monthly installments starting on July 29, 2026.
He was also granted 31,667 restricted share units, each representing one American Depositary Share, vesting in a single installment on June 29, 2027. Following these awards, his reported holdings in these instruments match the granted amounts.
Autolus Therapeutics plc director Rao Madduri Ravin received new equity awards in the form of options and restricted share units tied to American Depositary Shares. The grant includes 47,500 share options with a $1.61 exercise price expiring on June 29, 2036, and 31,667 restricted share units. The RSUs vest in a single installment on June 29, 2027, while the options vest in twelve equal monthly installments starting on July 29, 2026. These awards represent compensation-related acquisitions rather than open-market purchases or sales.
Autolus Therapeutics plc director Ryan Richardson received new equity awards in the form of options and restricted share units. He was granted options to buy 47,500 American Depositary Shares at an exercise price of $1.61 per share, expiring on June 29, 2036. These options vest in twelve equal monthly installments starting on July 29, 2026. He also received 31,667 restricted share units, each representing one American Depositary Share, which vest in a single installment on June 29, 2027. Following these grants, his reported holdings for these awards match the granted amounts, reflecting compensation rather than open‑market trading.
Autolus Therapeutics plc director Elisabeth Leiderman received new equity awards. She was granted options over 47,500 American Depositary Shares at an exercise price of $1.61 per share, vesting in twelve equal monthly installments starting on July 29, 2026, and 31,667 restricted share units that vest in one installment on June 29, 2027. Each RSU represents a right to receive one American Depositary Share, and each American Depositary Share is convertible into one Ordinary Share.
Autolus Therapeutics plc director Robert Iannone received new equity awards. He was granted options covering 47,500 American Depositary Shares at an exercise price of $1.6100 per share, vesting in twelve equal monthly installments starting on July 29, 2026, and expiring on June 29, 2036.
He also received 31,667 restricted share units, each representing one American Depositary Share, which will vest in a single installment on June 29, 2027. Each American Depositary Share is convertible into one ordinary share of Autolus Therapeutics.
Autolus Therapeutics plc director Cynthia M. Butitta received new equity awards. She was granted options to buy 47,500 shares of American Depositary Shares at an exercise price of $1.61 per share, expiring on June 29, 2036, vesting in twelve equal monthly installments starting July 29, 2026.
She also received 31,667 restricted share units, each representing one American Depositary Share, vesting in a single installment on June 29, 2027. These awards are compensation-related grants rather than open‑market purchases or sales.
Autolus Therapeutics plc director Linda Bain received new equity awards as part of her compensation. She was granted a share option covering 47,500 American Depositary Shares with an exercise price of $1.61 per share, expiring on June 29, 2036. These options vest in twelve equal monthly installments starting on July 29, 2026.
She also received 31,667 restricted share units, each representing a contingent right to one American Depositary Share. The RSUs vest in a single installment on June 29, 2027. Each American Depositary Share is convertible at any time into one ordinary share, providing future potential ownership if the awards vest and, for options, are exercised.
Autolus Therapeutics plc director Robert Azelby received new equity awards in the form of options and restricted share units tied to the company’s American Depositary Shares. On June 29, 2026, he was granted options over 47,500 ADSs at an exercise price of $1.61 per share, vesting in twelve equal monthly installments starting July 29, 2026. He also received 31,667 restricted share units covering 31,667 ADSs, which vest in a single installment on June 29, 2027. Each RSU represents a contingent right to receive one ADS, and each ADS is convertible into one ordinary share.
Autolus Therapeutics plc director Michael W. Bonney received new equity-based compensation. He was granted options to buy 47,500 American Depositary Shares at an exercise price of $1.61 per share, vesting in twelve equal monthly installments starting on July 29, 2026.
He also received 31,667 restricted share units, each representing one American Depositary Share, which vest in a single installment on June 29, 2027. These awards increase his potential future ownership but are subject to time-based vesting.